Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 3, 2006, Pages 201-215

  Alibhai, Shabbir M H ^a,b,c,d   Gogov, Sven ^a   Allibhai, Zishan ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adverse effects; Androgen deprivation therapy; Anemia; Cognitive function; Osteoporosis; Physical function; Quality of life

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARM MUSCLE; BONE DENSITY; BREAST TENDERNESS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE CONTROL; ENDOCRINE DISEASE; ENERGY; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; FRACTURE; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; MEDICAL LITERATURE; MENTAL DISEASE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MUSCLE ATROPHY; MUSCLE STRENGTH; MUSCULOSKELETAL DISEASE; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; PAIN; PHYSICAL ACTIVITY; PHYSICIAN; PROSTATE CANCER; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; THYROID DISEASE; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33750729609     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.06.006     Document Type: Review

References (136)

1. Huggins C., and Hodges C.V. The effect of castration and estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-299
2. Shahinian V.B., Kuo Y.F., Freeman J.L., Orihuela E., and Goodwin J.S. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 8 (2005) 1615-1624
3. Salminen E.K., Wickstrom J.E., Vahlberg T., and Duchesne G.M. Trends in the use of androgen deprivation in prostate cancer. Acta Oncol 43 4 (2004) 382-387
4. Petrylak D.P., and Moul J.W. Androgen ablation for prostate cancer: mechanisms and modalities. In: Kantoff P.W., Carroll P.R., and D'Amico A.V. (Eds). Prostate cancer: principles and practice (2002), Lippincott Williams and Wilkins, Philadelphia 518-523
5. National Cancer Institute of Canada: Canadian Cancer Statistics 2000. Toronto, 2000.
6. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
7. Bondy S.J., Iscoe N.A., Rothwell D.M., et al. Trends in hormonal management of prostate cancer: a population-based study in Ontario. Med Care 39 4 (2001) 384-396
8. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 13 (2003) 981-989
9. Park S., Meng M.V., Elkin E.P., Speight J.L., DuChane J., and Carroll P.R. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE. J Urol 174 5 (2005) 1802-1807
10. Zeliadt S.B., Potosky A.L., Etzioni R., Ramsey S.D., and Penson D.F. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends. Urology 64 6 (2004) 1171-1176
11. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
12. Akaza H., Homma Y., Okada K., et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU Int 91 1 (2003) 33-36
13. Williams S.G., Millar J.L., Dally M.J., Sia S., Miles W., and Duchesne G.M. What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys 58 1 (2004) 11-18
14. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Chen M.H. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer 97 1 (2003) 56-62
15. Alibhai S.M.H., Naglie G., Nam R., Trachtenberg J., and Krahn M.D. Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol 21 17 (2003) 3318-3327
16. Jani A.B., and Hellman S. Early prostate cancer: clinical decision-making. Lancet 361 9362 (2003) 1045-1053
17. Wirth M.P., See W.A., McLeod D.G., Iversen P., Morris T., and Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 5 Pt 1 (2004) 1865-1870
18. Iversen P., Johansson J.E., Lodding P., et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172 5 Pt 1 (2004) 1871-1876
19. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., and Kantoff P.W. Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 7 (2004) 821-827
20. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 5 (2001) 1243-1252
21. Pollack A., Kuban D.A., and Zagars G.K. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 60 3 Suppl 1 (2002) 22-30 discussion 30-1
22. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
23. Granfors T., Modig H., Damber J.E., and Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 159 6 (1998) 2030-2034
24. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 9327 (2002) 103-106
25. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 5 (2005) 1285-1290
26. Loblaw D.A., Mendelson D.S., Talcott J.A., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 14 (2004) 2927-2941
27. Tyrrell C.J., Payne H., See W.A., et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 76 1 (2005) 4-10
28. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
29. Walsh P.C., DeWeese T.L., and Eisenberger M.A. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 166 2 (2001) 508-515 discussion 515-6
30. Crawford E.D. Early versus late hormonal therapy: debating this issues. Urolology 61 2 Suppl 1 (2003) 8-13
31. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 2 (2004) 125-135
32. Albertsen P.C., Hanley J.A., Penson D.F., and Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171 6 Pt 1 (2004) 2221-2225
33. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 3 (2004) 1141-1147
34. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pre-treatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 4 (2005) 440-447
35. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 4 (2005) 433-439
36. Witjes W.P., Schulman C.C., and Debruyne F.M. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study group on Neoadjuvant Treatment of Prostate Cancer. Urology 49 Suppl 3A (1997) 65-69
37. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 1 (2002) 112-116
38. Klotz L.H., Goldenberg S.L., Jewett M.A., et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170 3 (2003) 791-794
39. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 1 (2004) 15-23
40. Herr H.W. Strategies for the management of recurrent and advanced urologic cancers. Quality of life. Cancer 60 3 Suppl (1987) 623-630
41. Presant C.A., Soloway M.S., Klioze S.S., et al. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life. Cancer 59 10 (1987) 1713-1716
42. Bennett C.L., Matchar D., McCrory D., McLeod D.G., Crawford E.D., and Hillner B.E. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?. Cancer 77 9 (1996) 1854-1861
43. Gleave M.E., Bruchovsky N., Moore M.J., and Venner P. Prostate cancer: 9 treatment of advanced disease. Can Med Assoc J 160 (1999) 225-232
44. Schroder F.H. Endocrine treatment of prostate cancer-recent developments and the future. Part 1. Maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int 83 2 (1999) 161-170
45. Fossa S.D., Aaronson N.K., Newling D., et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur J Cancer 26 11/12 (1990) 1133-1136
46. da Silva F.C., Reis E., Costa T., and Denis L. Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer 71 3 Suppl (1993) 1138-1142
47. Canadian study of health and aging: study methods and prevalence of, dementia. Can Med Assoc J 150 6 (1994) 899-913
48. Kurtz M.E., Kurtz J.C., Stommel M., Given C.W., and Given B. Loss of physical functioning among geriatric cancer patients: relationships to cancer site treatment, comorbidity and age. Eur J Cancer 33 14 (1997) 2352-2358
49. Stafford R.S., and Cyr P.L. The impact of cancer on the physical function of the elderly and their utilization of health care. Cancer 80 10 (1997) 1973-1980
50. Meyers C.A. Neurocognitive dysfunction in cancer patients. Oncology (Huntingt) 14 1 (2000) 75-79 discussion 79, 81, 82, 85
51. Kurtz M.E., Kurtz J.C., Stommel M., Given C.W., and Given B. Physical functioning and depression among older persons with cancer. Cancer Pract 9 1 (2001) 11-18
52. Given B., Given C., Azzouz F., and Stommel M. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 50 4 (2001) 222-232
53. Fossa S.D., Woehre H., Kurth K.-H., et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 31 Suppl 3 (1997) 3-8
54. Smith D.S., Carvalhal G.F., Schneider K., Krygiel J., Yan Y., and Catalona W.J. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer 88 6 (2000) 1454-1463
55. Potosky A.L., Reeve B.B., Clegg L.X., et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94 6 (2002) 430-437
56. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20 2 (2002) 557-566
57. Fowler Jr. F.J., McNaughton Collins M., Walker Corkery E., Elliott D.B., and Barry M.J. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95 2 (2002) 287-295
58. Lubeck D.P., Litwin M.S., Henning J.M., Stoddard M.L., Flanders S.C., and Carroll P.R. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology 53 1 (1999) 180-186
59. Herr H.W., and O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 6 (2000) 1743-1746
60. Lubeck D.P., Grossfeld G.D., and Carroll P.R. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 58 2 Suppl 1 (2001) 94-100
61. Green H.J., Pakenham K.I., Headley B.C., and Gardiner R.A. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 11 5 (2002) 401-414
62. van Andel G., and Kurth K.H. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 44 2 (2003) 209-214
63. Stone P., Hardy J., Huddart R., A'Hern R., and Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36 9 (2000) 1134-1141
64. Williams M.B., Hernandez J., and Thompson I. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol 173 4 (2005) 1067-1071
65. Basaria S., Lieb II J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford) 56 6 (2002) 779-786
66. Segal R.J., Reid R.D., Courneya K.S., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21 9 (2003) 1653-1659
67. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol 19 17 (2001) 3750-3757
68. Mathiowetz V., Kashman N., Volland G., Weber K., Dowe M., and Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 66 2 (1985) 69-74
69. Rantanen T., Volpato S., Ferrucci L., Heikkinen E., Fried L.P., and Guralnik J.M. Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. J Am Geriatr Soc 51 5 (2003) 636-641
70. Cherrier M.M., Asthana S., Plymate S., et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57 1 (2001) 80-88
71. Moffat S.D., Zonderman A.B., Metter E.J., Blackman M.R., Harman S.M., and Resnick S.M. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 87 11 (2002) 5001-5007
72. Sih R., Morley J.E., Kaiser F.E., Perry III H.M., Patrick P., and Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82 6 (1997) 1661-1667
73. Newton C., Slota D., Yuzpe A.A., and Tummon I.S. Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril 65 6 (1996) 1253-1255
74. Green H.J., Pakenham K.I., Headley B.C., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 4 (2002) 427-432
75. Green H.J., Pakenham K.I., Headley B.C., et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93 7 (2004) 975-979
76. Jenkins V.A., Bloomfield D.J., Shilling V.M., and Edginton T.L. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96 1 (2005) 48-53
77. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 5 (2003) 1808-1811
78. Salminen E., Portin R., Korpela J., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 89 6 (2003) 971-976
79. Salminen E.K., Portin R.I., Koskinen A., Helenius H., and Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10 22 (2004) 7575-7582
80. Almeida O.P., Waterreus A., Spry N., Flicker L., and Martins R.N. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29 8 (2004) 1071-1081
81. Salminen E.K., Portin R.I., Koskinen A.I., Helenius H.Y., and Nurmi M.J. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103 7 (2005) 1381-1387
82. Taxel P., Stevens M.C., Trahiotis M., Zimmerman J., and Kaplan R.F. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc 52 2 (2004) 269-273
83. Molinari P.F. Erythropoietic mechanism of androgens: a critical review and clinical implications. Haematologica 67 3 (1982) 442-460
84. Hamilton J.B. Role of testicular secretions as indicated by effects of castration in man and by studies of pathological conditions and short lifespan associated with maleness. Recent Progr Hormone Res 3 (1948) 257-289
85. Fonseca R., Rajkumar S.V., White W.L., Tefferi A., and Hoagland H.C. Anemia after orchiectomy. Am J Hematol 59 3 (1998) 230-233
86. Asbell S.O., Leon S.A., Tester W.J., Brereton H.D., Ago C.T., and Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 29 4 (1996) 243-248
87. Strum S.B., McDermed J.E., Scholz M.C., Johnson H., and Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 6 (1997) 933-941
88. Chander S., Choo R., Danjoux C., et al. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 62 3 (2005) 719-724
89. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., and Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 1 (2000) 181-186
90. Bergstrom I., Gustafsson H., Sjoberg K., and Arver S. Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer-a prospective, controlled, parallel-group study. Scand J Urol Nephrol 38 2 (2004) 148-152
91. Mittan D., Lee S., Miller E., Perez R.C., Basler J.W., and Bruder J.M. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 8 (2002) 3656-3661
92. Diamond T., Campbell J., Bryant C., and Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83 8 (1998) 1561-1566
93. Diamond T.H., Winters J., Smith A., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 6 (2001) 1444-1450
94. Nishiyama T., Ishizaki F., Anraku T., Shimura H., and Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocr Metab 90 2 (2005) 657-660
95. Sieber P.R., Keiller D.L., Kahnoski R.J., Gallo J., and McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171 6 Pt 1 (2004) 2272-2276 quiz 2435
96. Smith M.R., Goode M., Zietman A.L., McGovern F.J., Lee H., and Finkelstein J.S. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22 13 (2004) 2546-2553
97. Melton III L.J., Atkinson E.J., O'Connor M.K., O'Fallon W.M., and Riggs B.L. Bone density and fracture risk in men. J Bone Miner Res 13 12 (1998) 1915-1923
98. Nguyen T.V., and Eisman J.A. Risk factors for low bone mass in men. In: Orwoll E.S. (Ed). Osteoporosis in men (1999), Academic Press, San Diego 335-361
99. Center J.R., Nguyen T.V., Sambrook P.N., and Eisman J.A. Hormonal and biochemical parameters and osteoporotic fractures in elderly men. J Bone Miner Res 15 7 (2000) 1405-1411
100. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 2 (1997) 439-444
101. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 2 (2005) 154-164
102. Melton III L.J., Alothman K.I., Khosla S., Achenbach S.J., Oberg A.L., and Zincke H. Fracture risk following bilateral orchiectomy. J Urol 169 5 (2003) 1747-1750
103. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 13 (2001) 948-955
104. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 6 (2003) 2008-2012
105. Morabito N., Gaudio A., Lasco A., et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 19 11 (2004) 1766-1770
106. Smith M.R., Fallon M.A., Lee H., and Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocr Metab 89 8 (2004) 3841-3846
107. Magno C., Anastasi G., Morabito N., et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 47 5 (2005) 575-580 discussion 580-1
108. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 9 (2000) 604-610
109. Sato Y., Iwamoto J., Kanoko T., and Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165 15 (2005) 1743-1748
110. Higano C.S. Management of bone loss in men with prostate cancer. J Urol 170 6 Pt 2 (2003) S59-S63 discussion S64
111. Duncan G.G., Corbett T., Lukka H., Warde P., and Pickles T. GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13 1 (2006) 2962-2966
112. Dunzendorfer U., and Schulz H. Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate. Z Urol Nephrol 75 7 (1982) 493-500
113. Tayek J.A., Heber D., Byerley L.O., Steiner B., Rajfer J., and Swerdloff R.S. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 39 12 (1990) 1314-1319
114. Salminen E., Koskinen A., Backman H., and Nurmi M. Effect of adjuvant androgen deprivation on thyroid function tests in prostate cancer patients. Anticancer Drugs 15 4 (2004) 351-356
115. Morote J., Esquena S., Orsola A., et al. Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. Anticancer Drugs 16 8 (2005) 863-866
116. Garnick M.B., Pratt C.M., Campion M., and Shipley J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol 14S 15 Suppl (2004) 4578
117. Verhelst J., Denis L., Van Vliet P., et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 41 4 (1994) 525-530
118. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 164 5 (2000) 1579-1582
119. Iversen P. Antiandrogen monotherapy: indications and results. Urology 60 3 Suppl 1 (2002) 64-71
120. Klotz L.H., Herr H.W., Morse M.J., and Whitmore Jr. W.F. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58 11 (1986) 2546-2550
121. Sato N., Akakura K., Isaka S., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64 2 (2004) 341-345
122. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., and Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 5 (1995) 839-844 discussion 844-5
123. Higano C.S., Ellis W., Russell K., and Lange P.H. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 5 (1996) 800-804
124. Bouchot O., Lenormand L., Karam G., et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 38 5 (2000) 543-549
125. Malone S., Perry G., Segal R., Dahrouge S., and Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 96 4 (2005) 514-520
126. Kaku H., Saika T., Tsushima T., et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66 4 (2006) 439-444
127. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166 4 (2006) 465-471
128. Dacal K., Sereika S.M., and Greenspan S.L. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54 1 (2006) 85-90
129. Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., and Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161 4 (1999) 1219-1222
130. Preston D.M., Torrens J.I., Harding P., Howard R.S., Duncan W.E., and McLeod D.G. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 5 4 (2002) 304-310
131. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 6 (2002) 2361-2367 discussion 2367
132. Chen Z., Maricic M., Nguyen P., Ahmann F.R., Bruhn R., and Dalkin B.L. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95 10 (2002) 2136-2144
133. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocr Metab 87 2 (2002) 599-603
134. Smith M.R. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63 4 (2004) 742-745
135. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocr Metab 86 9 (2001) 4261-4267
136. Schover L.R., Fouladi R.T., Warneke C.L., et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 95 11 (2002) 2397-2407